Tempest Therapeutics, Inc. (TPST)
0.511
-0.01
(-2.16%)
USD |
NASDAQ |
Oct 23, 16:00
0.5183
+0.01
(+1.43%)
After-Hours: 20:00
Tempest Therapeutics Enterprise Value : 14.95M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 14.95M |
| October 22, 2026 | 15.13M |
| October 21, 2026 | 15.22M |
| October 20, 2026 | 15.99M |
| October 19, 2026 | 16.37M |
| October 16, 2026 | 16.76M |
| October 15, 2026 | 16.93M |
| October 14, 2026 | 16.93M |
| October 13, 2026 | 17.67M |
| October 12, 2026 | 18.65M |
| October 09, 2026 | 18.93M |
| October 08, 2026 | 19.09M |
| October 07, 2026 | 19.43M |
| October 06, 2026 | 19.36M |
| October 05, 2026 | 19.45M |
| October 02, 2026 | 19.74M |
| October 01, 2026 | 19.66M |
| September 30, 2026 | 20.11M |
| September 29, 2026 | 19.73M |
| September 28, 2026 | 20.07M |
| September 25, 2026 | 20.03M |
| September 24, 2026 | 20.36M |
| September 23, 2026 | 21.51M |
| September 22, 2026 | 22.76M |
| September 21, 2026 | 19.15M |
| Date | Value |
|---|---|
| September 18, 2026 | 22.25M |
| September 17, 2026 | 21.08M |
| September 16, 2026 | 26.12M |
| September 15, 2026 | 18.85M |
| September 14, 2026 | 19.31M |
| September 11, 2026 | 19.75M |
| September 10, 2026 | 19.61M |
| September 09, 2026 | 21.30M |
| September 08, 2026 | 22.56M |
| September 04, 2026 | 23.24M |
| September 03, 2026 | 23.56M |
| September 02, 2026 | 24.36M |
| September 01, 2026 | 23.56M |
| August 31, 2026 | 24.20M |
| August 28, 2026 | 23.72M |
| August 27, 2026 | 24.04M |
| August 26, 2026 | 24.04M |
| August 25, 2026 | 24.52M |
| August 24, 2026 | 24.36M |
| August 21, 2026 | 23.40M |
| August 20, 2026 | 23.08M |
| August 19, 2026 | 23.88M |
| August 18, 2026 | 23.88M |
| August 17, 2026 | 24.84M |
| August 14, 2026 | 23.00M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Anika Therapeutics, Inc. | 273.50M |
| Savara, Inc. | 724.16M |
| Vericel Corp. | 2.108B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.244M |
| Total Expenses (Quarterly) | 5.244M |
| EPS Diluted (Quarterly) | -0.3445 |
| Earnings Yield | -877.7% |
| Normalized Earnings Yield | -599.73 |